OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
July 21, 2020
Catalent has unveiled investment plans to create a European center of excellence for clinical biologics formulation development and drug product fill/finish services.
July 20, 2020
A strong immune response by patients receiving two doses of AZD1222 vaccine suggests a possible dosing strategy for COVID-19 vaccine.
July 08, 2020
VAR2 Pharmaceuticals has been selected for its development of a drug-conjugated malaria protein that potentially selectively binds to most human tumor types.
June 30, 2020
The company now offers its CONFIDENCE virus clearance services to support validation of viral clearance processes.
June 15, 2020
Citing clinical trial data that hydroxychloroquine did not show benefits for COVID-19 patients, FDA removes emergency use authorization for the drug as a treatment for the novel coronavirus.
June 08, 2020
Novavax announces DoD contract to produce 10 million doses of COVID-19 vaccine candidate.
June 01, 2020
The companies have entered into a manufacturing agreement for the fill finish supply of lenzilumab for the potential treatment of COVID-19.
The acquisition gives Novovax an annual operating capacity of more that one billion doses of COVID-19 vaccine antigen.
Achieving herd immunity will require testing, data, a vaccine, and public support.
Working with incubators can provide cell and gene therapy developers with more opportunities.